Australian medical device company, Oventus Medical Ltd. (ASX:OVN) is pleased to share Dr Chris Hart's interview on Financial News Network.
Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2VentTM is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.
For more information on Oventus' Sleep Treatment Platform, please visit http://www.oventus.com
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has today released its Appendix 4C - Quarterly cash flow report for the period ended 30 June 2017.
Oventus Medical Limited (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. Oventus wishes to advise that the closing date for the SPP will be extended from Wednesday 19 July 2017 to Monday 31 July 2017.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has received FDA 510k clearance for its O2Vent W device, an oral appliance intended to reduce or alleviate snoring and mild to moderate obstructive sleep apnoea.
Oventus Medical Ltd (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. The record date to be registered as a shareholder for participation in the SPP is Wednesday, 21 June 2017.
Oventus Medical Limited (ASX:OVN) announces that it has completed a first tranche placement of approximately 18 million shares to institutional and sophisticated investors at an issue price of $0.36 per share to raise approximately $6.5 million.
Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a world-wide distribution agreement with Hong Kong based Modern Dental Group (HKG:3600). This is in addition to the recent announcement of the co-manufacturing agreement between Oventus and Modern Dental.
Oventus Medical Ltd (ASX:OVN) is pleased to announce that low pressure CPAP without a mask is one step closer. Results from the initial pilot study generated significant interest when presented at the American Academy of Dental Sleep Medicine in Boston on June 2nd 2017. The conference is the premier world forum for the latest developments in dental sleep medicine.
Oventus Medical Ltd (ASX:OVN) are pleased to announce that C-PAP (Continuous Positive Airway Pressure) without a mask is one step closer signalling the first major change in sleep medicine in decades. The first patient has been recruited in the next stage of a trial combining an oral appliance and C-PAP.
Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a manufacturing agreement with Hong Kong based Modern Dental Group. Modern Dental have extensive expertise in the manufacture of dental appliances and hold the required quality management certifications for medical device manufacture.